Skip to main content
Equibles
URGN logo

URGN · UroGen Pharma Ltd.

Track URGN — free

Use URGN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about URGN

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$43.62 -1.88 (-4.13%) At close · Aug 28
Russell 2000 member Rebalance outlook locked
Going-concern doubt — cleared Aug 5, 2026

The latest filing states the doubt was alleviated.

“Based on our cash and cash equivalents and marketable securities as of June 30, 2026, together with management's cash flow projections, we believe we have sufficient cash and cash equivalents to fund our operations beyond one year from the issuance of our condensed consolidated financial statements appearing elsewhere in this Quarterly Report.”
View the 10-Q filed Aug 5, 2026
Market Cap
$2.13B
Shares
48.88M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$43.62 Open$45.09 Day$43.39–45.54 52W close$16.42–50.29 Avg vol 30d878K Short int5.1M · 10.5% float · 4.8d Short vol45% Last earningsAug 5, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Nov 4, 2026 Est · unconfirmed · in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 5, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 14.4 · calm Equity put/call 0.62
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg +57%
      above
      Price vs 50-day avg +5%
      above
      RSI (14) 46
      neutral
      MACD trend Negative
      52-week position 80%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +14%
      trailing
      6-month return +119%
      trailing
      YTD return +86%
      this year
      Relative strength +106%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $42 › 200d $28 — 50d above 200d
      Institutional flow Accumulating
      +9% holders QoQ · +39 funds added
      Insider flow Distributing
      Net -$3.0M over 90 days · 100% sells
      Short interest Rising
      10.48% of float · ▲ +11.6% MoM · 4.8 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      190 holders — near 3-yr high, broad support
      Squeeze score 76
      high risk · 0–100
      Fundamentals
      Weak
      Revenue growth −86%
      Y/Y
      Gross margin 8630%
      expanding
      Free cash flow $-162.7M
      Balance sheet $14.3M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 67%
      annualized · 1-yr
      Max drawdown −42%
      past year
      ATR 4.7%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Aug 5, 2026
      2026 net product revenue for JELMYTO · full-year 2026 Maintained $97M – $101M
      May 6, 2026 $97M – $101M changed to Aug 5, 2026 $97M – $101M
      Full-year 2026 operating expenses · full-year 2026 Raised $260M – $270M
      May 6, 2026 $240M – $250M changed to Aug 5, 2026 $260M – $270M
      Non-cash share-based compensation expense · full-year 2026 Maintained $20M – $24M
      Jun 30, 2026 $20M – $24M changed to Aug 5, 2026 $20M – $24M
      Prior guidance period ended · from the 8-K filed Nov 6, 2025
      Net product revenues for JELMYTO · full-year 2025 $94M – $98M
      Operating expenses · full-year 2025 $215M – $225M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 4 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +57% Bullish
      Price vs 50-day avg
      +5% Bullish
      RSI (14)
      46 Neutral
      MACD trend
      Negative Bearish
      52-week position
      80% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $42 › 200d $28 — 50d above 200d
      Institutional flow Accumulating
      +9% holders QoQ · +39 funds added
      Insider flow Distributing
      Net -$3.0M over 90 days · 100% sells
      Short interest Rising
      10.48% of float · ▲ +11.6% MoM · 4.8 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      190 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $16 Now $44 · 80% Range high $50
      vs 200-day avg +57% vs 50-day avg +5%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      repeat ZUSDURI prescribers percentage of total prescribers 45% second quarter 2026 —
      JELMYTO year-over-year revenue growth 7% first quarter of 2026 —
      ZUSDURI quarter-over-quarter revenue growth 109% first quarter of 2026 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      URGN
      UroGen Pharma Ltd.
      this stock
      		$2.13B +86.3% -86.2% — 10.5%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $137.30B +19.5% +46.2% 31.6 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $81.27B +2.9% +20.8% 19.6 2.3%
      ARGX
      Argenx SE
      		 $63.63B +21.7% — — 1.9%
      CSLLY
      Csl Ltd
      		 $59.23B — — — 0.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      190
      % held
      87.6%
      Net QoQ
      -4.0M sh
      Top holder
      RTW INVESTMENTS, LP
      Held Float
      View
      Held by Funds
      Fund positions
      46
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      5.1M
      Days to cover
      4.8d
      Change
      +531.3K sh
      View
      Short Volume
      Short vol %
      45%
      As of
      Aug 28, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      109
      Value
      $4.3K
      As of
      Jul 16, 2026
      View
      Off-Exchange
      Off-exchange %
      42.9%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$3.0M
      Buyers / Sellers
      0 / 1
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $109.8M
      Net income (FY)
      $-153.5M
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 20, 2026
      This year
      12
      View
      Proposed Sales
      Value
      $2.9M
      Shares
      60.7K
      Filed
      Aug 20, 2026
      View
      Exempt Offerings
      Offering
      $120.0M
      Filed
      Aug 14, 2023
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 5, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      URGN -6.9% +14.1% +119.1% +14.1% +86.3%
      SPY +0.5% +3.0% +13.4% +3.0% +12.8%
      vs SPY -7.4% +11.1% +105.7% +11.1% +73.4%
      Key facts CIK 1668243 CUSIP M96088105 13F (30d) 167 filings 167 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)